Click here to get full coverage on MBRX Stock Price, Quote & Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - chartmill.com

MBRX Stock Price, Quote & Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX)  chartmill.com

MBRX Stock Price, Quote & Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - chartmill.com

Click here to get full coverage on Leukemia drug study reaches key 45-patient mark with results due mid-2026 - Stock Titan

Leukemia drug study reaches key 45-patient mark with results due mid-2026  Stock Titan

Leukemia drug study reaches key 45-patient mark with results due mid-2026 - Stock Titan

Click here to get full coverage on MBRX: HC Wainwright & Co. Reiterates Buy Rating and Price Target - GuruFocus

MBRX: HC Wainwright & Co. Reiterates Buy Rating and Price Target  GuruFocus

MBRX: HC Wainwright & Co. Reiterates Buy Rating and Price Target - GuruFocus

Click here to get full coverage on Moleculin Biotech files to sell 6.37M shares of common stock for holders - MSN

Moleculin Biotech files to sell 6.37M shares of common stock for holders  MSN

Moleculin Biotech files to sell 6.37M shares of common stock for holders - MSN

Click here to get full coverage on Moleculin (NASDAQ: MBRX) hits 45-subject milestone in pivotal MIRACLE AML trial - Stock Titan

Moleculin (NASDAQ: MBRX) hits 45-subject milestone in pivotal MIRACLE AML trial  Stock Titan

Moleculin (NASDAQ: MBRX) hits 45-subject milestone in pivotal MIRACLE AML trial - Stock Titan

Click here to get full coverage on MBRX Stock Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - chartmill.com

MBRX Stock Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX)  chartmill.com

MBRX Stock Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - chartmill.com

Click here to get full coverage on Moleculin Biotech (MBRX) Advances Phase 2B/3 Trial for Acute Mye - GuruFocus

Moleculin Biotech (MBRX) Advances Phase 2B/3 Trial for Acute Mye  GuruFocus

Moleculin Biotech (MBRX) Advances Phase 2B/3 Trial for Acute Mye - GuruFocus

Click here to get full coverage on If You Invested $1,000 in Moleculin Biotec (MBRX) - Stock Titan

If You Invested $1,000 in Moleculin Biotec (MBRX)  Stock Titan

If You Invested $1,000 in Moleculin Biotec (MBRX) - Stock Titan

Click here to get full coverage on Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout - chartmill.com

Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout  chartmill.com

Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout - chartmill.com

Click here to get full coverage on Moleculin leaders set for March 24 ROTH healthcare investor chat - Stock Titan

Moleculin leaders set for March 24 ROTH healthcare investor chat  Stock Titan

Moleculin leaders set for March 24 ROTH healthcare investor chat - Stock Titan

Click here to get full coverage on Moleculin's leukemia drug heads for a 45-patient readout in 2026 - Stock Titan

Moleculin's leukemia drug heads for a 45-patient readout in 2026  Stock Titan

Moleculin's leukemia drug heads for a 45-patient readout in 2026 - Stock Titan

Click here to get full coverage on Moleculin Biotech (NASDAQ: MBRX) registers 6.37M resale shares tied to warrants - Stock Titan

Moleculin Biotech (NASDAQ: MBRX) registers 6.37M resale shares tied to warrants  Stock Titan

Moleculin Biotech (NASDAQ: MBRX) registers 6.37M resale shares tied to warrants - Stock Titan

Click here to get full coverage on MBRX SEC Filings - Moleculin Biotec 10-K, 10-Q, 8-K Forms - Stock Titan

MBRX SEC Filings - Moleculin Biotec 10-K, 10-Q, 8-K Forms  Stock Titan

MBRX SEC Filings - Moleculin Biotec 10-K, 10-Q, 8-K Forms - Stock Titan

Click here to get full coverage on Moleculin (Nasdaq: MBRX) details 2025 loss and MIRACLE AML trial progress - Stock Titan

Moleculin (Nasdaq: MBRX) details 2025 loss and MIRACLE AML trial progress  Stock Titan

Moleculin (Nasdaq: MBRX) details 2025 loss and MIRACLE AML trial progress - Stock Titan

Click here to get full coverage on Leukemia trial update: Moleculin CEO explains MIRACLE drug study - Stock Titan

Leukemia trial update: Moleculin CEO explains MIRACLE drug study  Stock Titan

Leukemia trial update: Moleculin CEO explains MIRACLE drug study - Stock Titan

Click here to get full coverage on [8-K] Moleculin Biotech, Inc. Reports Material Event - Stock Titan

[8-K] Moleculin Biotech, Inc. Reports Material Event  Stock Titan

[8-K] Moleculin Biotech, Inc. Reports Material Event - Stock Titan

Click here to get full coverage on Chemo without heart damage? Leukemia drug trial sees 40% remission rate - Stock Titan

Chemo without heart damage? Leukemia drug trial sees 40% remission rate  Stock Titan

Chemo without heart damage? Leukemia drug trial sees 40% remission rate - Stock Titan

Click here to get full coverage on Moleculin’s $8.3M warrant deal: 2,122,652 shares now, 6,367,956 new warrants - Stock Titan

Moleculin’s $8.3M warrant deal: 2,122,652 shares now, 6,367,956 new warrants  Stock Titan

Moleculin’s $8.3M warrant deal: 2,122,652 shares now, 6,367,956 new warrants - Stock Titan

Click here to get full coverage on Moleculin Biotech releases CEO update on leukemia trial - Investing.com

Moleculin Biotech releases CEO update on leukemia trial  Investing.com

Moleculin Biotech releases CEO update on leukemia trial - Investing.com

Click here to get full coverage on Experimental chemo aiming to spare the heart nears key 2026 trial test - Stock Titan

Experimental chemo aiming to spare the heart nears key 2026 trial test  Stock Titan

Experimental chemo aiming to spare the heart nears key 2026 trial test - Stock Titan

Click here to get full coverage on New Moleculin CEO Corner invites investor questions on trials, strategy - Stock Titan

New Moleculin CEO Corner invites investor questions on trials, strategy  Stock Titan

New Moleculin CEO Corner invites investor questions on trials, strategy - Stock Titan

Click here to get full coverage on Why Did MBRX Stock Climb 14% Today? - Stocktwits

Why Did MBRX Stock Climb 14% Today?  Stocktwits

Why Did MBRX Stock Climb 14% Today? - Stocktwits

Click here to get full coverage on Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛

Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $10  富途牛牛

Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛

Click here to get full coverage on Moleculin Biotech (MBRX) price target decreased by 13.70% to 21.42 - MSN

Moleculin Biotech (MBRX) price target decreased by 13.70% to 21.42  MSN

Moleculin Biotech (MBRX) price target decreased by 13.70% to 21.42 - MSN

Click here to get full coverage on $MBRX stock is down 17% today. Here's what we see in our data. - Quiver Quantitative

$MBRX stock is down 17% today. Here's what we see in our data.  Quiver Quantitative

$MBRX stock is down 17% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Moleculin Biotech (Nasdaq: MBRX) enters warrant exercise deals for approx $6.5M - Stock Titan

Moleculin Biotech (Nasdaq: MBRX) enters warrant exercise deals for approx $6.5M  Stock Titan

Moleculin Biotech (Nasdaq: MBRX) enters warrant exercise deals for approx $6.5M - Stock Titan

Click here to get full coverage on Moleculin to Present at 38th Annual ROTH Conference - Sahm

Moleculin to Present at 38th Annual ROTH Conference  Sahm

Moleculin to Present at 38th Annual ROTH Conference - Sahm

Click here to get full coverage on Moleculin enrolls 45th patient in pivotal AML trial - Investing.com

Moleculin enrolls 45th patient in pivotal AML trial  Investing.com

Moleculin enrolls 45th patient in pivotal AML trial - Investing.com

Click here to get full coverage on Moleculin CEO Walter Klemp to speak at Webull’s Corporate Connect webinar - Stock Titan

Moleculin CEO Walter Klemp to speak at Webull’s Corporate Connect webinar  Stock Titan

Moleculin CEO Walter Klemp to speak at Webull’s Corporate Connect webinar - Stock Titan

Click here to get full coverage on Moleculin Biotech, Inc. Announces 1-for-25 Reverse Stock Split Effective December 1, 2025 - Quiver Quantitative

Moleculin Biotech, Inc. Announces 1-for-25 Reverse Stock Split Effective December 1, 2025  Quiver Quantitative

Moleculin Biotech, Inc. Announces 1-for-25 Reverse Stock Split Effective December 1, 2025 - Quiver Quantitative

Click here to get full coverage on Moleculin Biotech reports FY2025 net loss $33.6M, cash $8.9M; MIRACLE interim CRc 40% - TradingView

Moleculin Biotech reports FY2025 net loss $33.6M, cash $8.9M; MIRACLE interim CRc 40%  TradingView

Moleculin Biotech reports FY2025 net loss $33.6M, cash $8.9M; MIRACLE interim CRc 40% - TradingView

Click here to get full coverage on Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study - GlobeNewswire

Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study  GlobeNewswire

Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study - GlobeNewswire

Click here to get full coverage on Moleculin Biotech Updates Investors with New Corporate Presentation - TipRanks

Moleculin Biotech Updates Investors with New Corporate Presentation  TipRanks

Moleculin Biotech Updates Investors with New Corporate Presentation - TipRanks

Click here to get full coverage on Scalable Biotech Manufacturing Unlocks a $14B Market - theglobeandmail.com

Scalable Biotech Manufacturing Unlocks a $14B Market  theglobeandmail.com

Scalable Biotech Manufacturing Unlocks a $14B Market - theglobeandmail.com

Click here to get full coverage on Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds - GlobeNewswire

Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds  GlobeNewswire

Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds - GlobeNewswire

Click here to get full coverage on MBRX Stock Reverse Split 2025 Amid Biotech Bankruptcies: Analysts Remain Bullish - Bitget

MBRX Stock Reverse Split 2025 Amid Biotech Bankruptcies: Analysts Remain Bullish  Bitget

MBRX Stock Reverse Split 2025 Amid Biotech Bankruptcies: Analysts Remain Bullish - Bitget

Click here to get full coverage on Moleculin Advances MIRACLE Trial, Prepares Interim AML Readout - TipRanks

Moleculin Advances MIRACLE Trial, Prepares Interim AML Readout  TipRanks

Moleculin Advances MIRACLE Trial, Prepares Interim AML Readout - TipRanks

Click here to get full coverage on Why Did MBRX Stock Plummet Over 25% Today? - Stocktwits

Why Did MBRX Stock Plummet Over 25% Today?  Stocktwits

Why Did MBRX Stock Plummet Over 25% Today? - Stocktwits

Click here to get full coverage on Moleculin Biotech stock plunges after warrant exercise agreement - Investing.com

Moleculin Biotech stock plunges after warrant exercise agreement  Investing.com

Moleculin Biotech stock plunges after warrant exercise agreement - Investing.com

Click here to get full coverage on Moleculin Biotech Secures Up To $8.3 Million Via Warrant Exercise; Issues 300% Series H Warrants - TradingView

Moleculin Biotech Secures Up To $8.3 Million Via Warrant Exercise; Issues 300% Series H Warrants  TradingView

Moleculin Biotech Secures Up To $8.3 Million Via Warrant Exercise; Issues 300% Series H Warrants - TradingView

Click here to get full coverage on Moleculin Biotech (NASDAQ: MBRX) restores Nasdaq compliance and averts delisting risk - Stock Titan

Moleculin Biotech (NASDAQ: MBRX) restores Nasdaq compliance and averts delisting risk  Stock Titan

Moleculin Biotech (NASDAQ: MBRX) restores Nasdaq compliance and averts delisting risk - Stock Titan

Click here to get full coverage on Moleculin (NASDAQ: MBRX) presents Phase 3 MIRACLE AML trial of AnnAraC regimen - Stock Titan

Moleculin (NASDAQ: MBRX) presents Phase 3 MIRACLE AML trial of AnnAraC regimen  Stock Titan

Moleculin (NASDAQ: MBRX) presents Phase 3 MIRACLE AML trial of AnnAraC regimen - Stock Titan

Click here to get full coverage on Market Movers | Winners: ADVB, KNRX, DRMA | Losers: MBRX, ALIT, DBGI - Trefis

Market Movers | Winners: ADVB, KNRX, DRMA | Losers: MBRX, ALIT, DBGI  Trefis

Market Movers | Winners: ADVB, KNRX, DRMA | Losers: MBRX, ALIT, DBGI - Trefis

Click here to get full coverage on Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ  StocksToTrade

Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Click here to get full coverage on Moleculin Biotech (MBRX) Readies Annamycin for Major Milestones in 2026 - GuruFocus

Moleculin Biotech (MBRX) Readies Annamycin for Major Milestones in 2026  GuruFocus

Moleculin Biotech (MBRX) Readies Annamycin for Major Milestones in 2026 - GuruFocus

Click here to get full coverage on Moleculin Announces Reverse Stock Split - GlobeNewswire

Moleculin Announces Reverse Stock Split  GlobeNewswire

Moleculin Announces Reverse Stock Split - GlobeNewswire

Click here to get full coverage on Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30) - GlobeNewswire

Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)  GlobeNewswire

Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30) - GlobeNewswire

Click here to get full coverage on Moleculin Biotech (MBRX) Target Price Adjusted by Roth Capital A - GuruFocus

Moleculin Biotech (MBRX) Target Price Adjusted by Roth Capital A  GuruFocus

Moleculin Biotech (MBRX) Target Price Adjusted by Roth Capital A - GuruFocus

Click here to get full coverage on Moleculin Biotech Issues New Investor Corporate Presentation - TipRanks

Moleculin Biotech Issues New Investor Corporate Presentation  TipRanks

Moleculin Biotech Issues New Investor Corporate Presentation - TipRanks

Click here to get full coverage on Moleculin Biotech Shareholders Approve Warrant Share Issuance - TipRanks

Moleculin Biotech Shareholders Approve Warrant Share Issuance  TipRanks

Moleculin Biotech Shareholders Approve Warrant Share Issuance - TipRanks

Click here to get full coverage on Moleculin Biotech (MBRX) Gains Japanese Patent Progress for Lipo - GuruFocus

Moleculin Biotech (MBRX) Gains Japanese Patent Progress for Lipo  GuruFocus

Moleculin Biotech (MBRX) Gains Japanese Patent Progress for Lipo - GuruFocus

Click here to get full coverage on Moleculin Biotech’s Bold Move: Stock Split Announced - StocksToTrade

Moleculin Biotech’s Bold Move: Stock Split Announced  StocksToTrade

Moleculin Biotech’s Bold Move: Stock Split Announced - StocksToTrade

Click here to get full coverage on Moleculin Biotech Raises Capital via Inducement Warrant Agreements - theglobeandmail.com

Moleculin Biotech Raises Capital via Inducement Warrant Agreements  theglobeandmail.com

Moleculin Biotech Raises Capital via Inducement Warrant Agreements - theglobeandmail.com

Click here to get full coverage on Moleculin Biotech stock faces bearish sentiment amid clinical-stage challenges in oncology pipeline - AD HOC NEWS

Moleculin Biotech stock faces bearish sentiment amid clinical-stage challenges in oncology pipeline  AD HOC NEWS

Moleculin Biotech stock faces bearish sentiment amid clinical-stage challenges in oncology pipeline - AD HOC NEWS

Click here to get full coverage on Moleculin Biotech raises $8.3 million through warrant exercise - Investing.com

Moleculin Biotech raises $8.3 million through warrant exercise  Investing.com

Moleculin Biotech raises $8.3 million through warrant exercise - Investing.com

Click here to get full coverage on Moleculin Biotech Raises Capital via Inducement Warrant Agreements - TipRanks

Moleculin Biotech Raises Capital via Inducement Warrant Agreements  TipRanks

Moleculin Biotech Raises Capital via Inducement Warrant Agreements - TipRanks

Click here to get full coverage on Moleculin Reports Positive Progress in MIRACLE AML Trial - TipRanks

Moleculin Reports Positive Progress in MIRACLE AML Trial  TipRanks

Moleculin Reports Positive Progress in MIRACLE AML Trial - TipRanks

Click here to get full coverage on Moleculin reports 40% preliminary CRc in MIRACLE trial; 35 treated, 45-subject unblinding on track - TradingView

Moleculin reports 40% preliminary CRc in MIRACLE trial; 35 treated, 45-subject unblinding on track  TradingView

Moleculin reports 40% preliminary CRc in MIRACLE trial; 35 treated, 45-subject unblinding on track - TradingView

Click here to get full coverage on Moleculin Biotech’s Reverse Split Shocks Market - timothysykes.com

Moleculin Biotech’s Reverse Split Shocks Market  timothysykes.com

Moleculin Biotech’s Reverse Split Shocks Market - timothysykes.com

Click here to get full coverage on The MIRACLE Test: Trial Progress And Market Moves Put Moleculin In Focus - RTTNews

The MIRACLE Test: Trial Progress And Market Moves Put Moleculin In Focus  RTTNews

The MIRACLE Test: Trial Progress And Market Moves Put Moleculin In Focus - RTTNews

Click here to get full coverage on Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin - GlobeNewswire

Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin  GlobeNewswire

Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin - GlobeNewswire

Click here to get full coverage on Moleculin Biotech Regains Compliance With Nasdaq Listing Requirements - theglobeandmail.com

Moleculin Biotech Regains Compliance With Nasdaq Listing Requirements  theglobeandmail.com

Moleculin Biotech Regains Compliance With Nasdaq Listing Requirements - theglobeandmail.com

Click here to get full coverage on Moleculin to Present at 38th Annual ROTH Conference - The Manila Times

Moleculin to Present at 38th Annual ROTH Conference  The Manila Times

Moleculin to Present at 38th Annual ROTH Conference - The Manila Times

Click here to get full coverage on Moleculin Biotech (MBRX): Tiny Cancer Stock, Massive Hype – Is It About To Explode Or Implode? - AD HOC NEWS

Moleculin Biotech (MBRX): Tiny Cancer Stock, Massive Hype – Is It About To Explode Or Implode?  AD HOC NEWS

Moleculin Biotech (MBRX): Tiny Cancer Stock, Massive Hype – Is It About To Explode Or Implode? - AD HOC NEWS

Click here to get full coverage on Moleculin Biotech Appeals Nasdaq Delisting Decision - theglobeandmail.com

Moleculin Biotech Appeals Nasdaq Delisting Decision  theglobeandmail.com

Moleculin Biotech Appeals Nasdaq Delisting Decision - theglobeandmail.com

Click here to get full coverage on Moleculin expects first MIRACLE trial data readout in Q1 2026 - Investing.com

Moleculin expects first MIRACLE trial data readout in Q1 2026  Investing.com

Moleculin expects first MIRACLE trial data readout in Q1 2026 - Investing.com

Click here to get full coverage on Moleculin Biotech regains compliance with Nasdaq minimum bid price rule By Investing.com - Investing.com South Africa

Moleculin Biotech regains compliance with Nasdaq minimum bid price rule By Investing.com  Investing.com South Africa

MBRX

Price Chart

Key Statistics

Technicals

About MBRX

Latest News

MBRX Stock Price, Quote & Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - chartmill.com

Leukemia drug study reaches key 45-patient mark with results due mid-2026 - Stock Titan

MBRX: HC Wainwright & Co. Reiterates Buy Rating and Price Target - GuruFocus

Advanced Charts

Top Gainers

Top Losers